Pfizer Inc. boosts its oncology pipeline with strategic control of PD-1/VEGF bispecific drugs via 3SBio deal. Click for more ...

Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...

Pfizer’s stock surged up to 11 percent after the pharma giant reported a robust 85 percent year-on-year rise in net profit ...

There are instances where high-yielding stocks can simply be great deals. Three stocks that pay at least 6% and don't look ...

These four quality stocks trading at or near their 52-week lows come with stellar dividends that could be massive bargains ...

Pfizer Inc (NYSE:PFE) shares are moving higher Tuesday following multiple developments. Here's a look at what's going on.

Pfizer closes a deal on a new Cancer drug. The stock is pacing for 4th day of gains. The Investment Committee debate the ...

The stock jumped 11.91% during the day to touch a high of Rs 4,995.85 on the stock exchanges, after starting the day at Rs ...

According to Benzinga Pro, Pfizer's peer group average for short interest as a percentage of float is 3.60%, which means the ...

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s ...

3SBio's shares surged 32% to 19.18 Hong Kong dollars, equivalent to US$2.45, on Tuesday after the Chinese company said it would receive an upfront payment of US$1.25 billion and potential milestone ...

The declines in these stocks reflect the overall market dynamics and sector-specific challenges faced by these companies ...